Solid body forms of mesoprogestin 11β-{4E-(hydroxyiminomethyl)-phenyl}-17α methoxymethyl-17β-methoxy-estra-4,9-dien-3-one

US7799770B2 · kind B2 · utility

Assignee

• Bayer Schering Pharma AG · DE

Inventors

• Detlef Grawe · Kleinromstedt, DE
• Peter Hosel · Munich, DE
• Uwe Muller · Linz, AT
• Gabriele Winter · Lübbenau/Spreewald - Lubnjow/Błota, DE

Key dates

• Filing date: May 9, 2001
• Grant date: Sep 21, 2010
• Expiry date: Jul 6, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07J41/0083
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel solid body forms of mesoprogestin 11β-[4E-(hydroxyiminomethyl)-phenyl]-17α-methoxymethyl-17β-methoxy-estra-4,9-dien-3-one (oxime J 867), particularly a highly pure and stable amorphous or highly crystalline form (ansolvate/anhydrate) of compound J 867. The invention also relates to methods for producing said novel solid body forms and to the use thereof in pharmaceutical compositions. The novel solid body forms are characterized by exhibiting a high degree of stability. The solid body forms of oxime J 867 can, in particular, be used in the area of fertility control and in hormone replacement therapy.